Ixabepilone Injection

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.NCT04796324Allarity TherapeuticsPhase 2Terminated2024-12-01Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.